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Aims We evaluated the feasibility and the acute performance of the everolimus-eluting bioresorbable vascular scaffolds (BVS)
for the treatment of patients presenting with ST-segment elevation myocardial infarction (STEMI).
Methods
and results
The present investigation is a prospective, single-arm, single-centre study, reporting data after the BVS implantation in
STEMI patients. Quantitative coronaryangiographyand optical coherence tomography (OCT) datawere evaluated. Clin-
ical outcomes are reported at the 30-day follow-up. The intent-to-treat population comprises a total of 49 patients. The
procedural successwas97.9%. Pre-procedureTIMI-flowwas0 in50.0%of the patients; after the BVS implantation, aTIMI-
flow III was achieved in 91.7% of patients and the post-procedure percentage diameter stenosis was 14.7+ 8.2%. No
patients had angiographically visible residual thrombus at the end of the procedure. Optical coherence tomography ana-
lysis performed in 31 patients showed that the post-procedure mean lumen area was 8.02+1.92 mm2, minimum lumen
area 5.95+1.61 mm2, mean incomplete scaffold apposition area 0.118+0.162 mm2, mean intraluminal defect area
0.013+0.017 mm2, and mean percentage malapposed struts per patient 2.80+3.90%. Scaffolds with.5% malapposed
struts were 7. At the 30-day follow-up, target-lesion failure rate was 0%. Non-target-vessel revascularization and target-
vesselmyocardial infarction (MI)werereported. Anon-target-vessel non-Q-waveMIoccurred.Nocasesof cardiacdeath
or scaffold thrombosis were observed.
Conclusion In the present series, the BVS implantation in patients presenting with acute MI appeared feasible, with high rate of final
TIMI-flow III and good scaffold apposition. Larger studies are currently needed to confirm these preliminary data.
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Introduction
Primary percutaneous coronary intervention has been demon-
strated to be superior to thrombolytic strategy and is currently the
treatment of first choice for patients presenting with ST-segment ele-
vation myocardial infarction (STEMI) in experienced centres with
limited time delay.1 First-generation drug-eluting stents (DES) have
been shown to reduce the need for repeat revascularization com-
pared with bare-metal stents (BMS),2 –4 and the newer-generation
DES with improved biocompatibility of polymers may lower the
rate of clinical events also in acute patients.5,6 However, the implant-
ation of metal devices is not devoid of important limitations, such as
permanent caging of the vesselwith permanent impairment of coron-
ary vasomotion, side branch jailing, impossibility of late lumen
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enlargement, non-invasive imaging and future surgical revasculariza-
tion of stented segments.7 Moreover, in spite of the beneficial effect
of neointimal inhibition, the antiproliferative drug elution has been
shown to interfere with the vascular healing processes providing
the background for delayed strut coverage and persistent or acquired
malapposition.8,9 The above-mentioned limitations can be proposed
for both stable and acute patients; however, primary stenting has add-
itional specific characteristics that should be highlighted. Stent place-
ment in acute thrombotic lesions has been reported to be an
independent predictor of late stent malapposition after the BMS10
or DES11 implantation. Possible explanations for this phenomenon
could be the thrombus sequestration behind the struts—which sub-
sequently resolves—and the vasoconstriction during the acute
phase. Both these factors may predispose to stent under-
deployment, malapposition and finally to stent thrombosis. The
everolimus-eluting bioresorbable vascular scaffold (BVS) has been
designed to overcome the general limitations of the metallic stents
and recently has been shown to provide excellent results for the
treatment of stable patients.12,13 However, so far very limited data
are available on the use of this novel device in patients with acute
coronary syndromes (ACS).14,15 Given this background, a pilot
study investigating the feasibility and acute performance of the BVS
for the treatment of patients presenting with STEMI was initiated.
Methods
Rationale
As of 1 September 2012, the BVS (ABSORB; Abbott Vascular, Santa
Clara, CA, USA) has been commercially available in the Netherlands.
Based on previous experience and available evidence, reported in
ABSORB Cohort A and B Trial13,16 our institution initiated the use
of BVS for the treatment of patients presenting for PCI in everyday
clinical practice, with a preference for patients with a good life ex-
pectancy as demonstrated by the presence of limited co-morbidities.
As these patients might have more complex lesions compared with
the ABSORB study patients16,17 the BVS-EXPAND registry was
initiated. The BVS-EXPAND also included patients with ACS (un-
stable angina or non-STEMI). After the first experience with ACS
patients and an interim analysis, a decision was made to extend
BVS utilization to the treatment of STEMI.
As an additional measure for assessing the safety of a treatment ap-
proach with BVS in STEMI, optical coherence tomography (OCT)
imaging was performed, according to clinical judgement, for a more
comprehensive evaluation of the acute procedural outcome.
Study design
The present report is an investigator initiated, prospective, single-
arm, single-centre study to assess feasibility and performance of
the second-generation everolimus-eluting BVS for the treatment of
patients presenting with STEMI.
Subjects enrolled were patients of ≥18-year-old admitted with
STEMI, defined as at least 1 mm ST-segment elevation in two or
more standard leads or at least 2 mm in two or more contiguous pre-
cordial leads or new left bundle branch block within 12 h after the
onset of symptoms. Culprit lesions were located in vessels within
the upper limit of 3.8 mm and the lower limit of 2.0 mm by online
quantitative coronary angiography (QCA). The absorb BVS was
implanted according to the manufacturer’s indication on target-
vessel diameter ranges and absorb BVS diameters to be used. The
absorb BVS with a nominal diameter of 2.5 mm was implanted in
vessels ≥2.0 and ≤3.0 mm by online QCA; the 3.0 mm BVS was
implanted in vessels ≥2.5 and ≤3.3 mm by online QCA; the
3.5 mm BVS was implanted in vessels ≥3.0 and ≤3.8 mm. Given
the manufacturer’s indication on maximum scaffold expansion, for
each nominal diameter a further expansion of 0.5 mm was allowed.
Enrolled subjects were willing to comply with specified follow-up
evaluation and to be contacted by telephone. Exclusion criteria com-
prise pregnancy, known intolerance to contrast medium, uncertain
neurological outcome after cardiopulmonary resuscitation, previous
percutaneous coronary intervention with the implantation of a metal
stent, left main (LM) disease previous coronary artery bypass grafting
(CABG), age superior to 75 years, and participation to another inves-
tigational drug or device study before reaching the primary endpoints.
The enrolment period started on 1 November 2012 and ended on 30
March 2013. Dual antiplatelet therapy after the BVS implantation was
planned to have a duration of 12 months. Baseline and post-BVS im-
plantation QCA analysis, OCT analyses at post-BVS implantation,
and clinical outcomes at the 30-day follow-up were evaluated.
Definitions
Success rates were defined as follows: device success was the attain-
ment of ,30% final residual stenosis of the segment of the culprit
lesion covered by the BVS, by angiographic visual estimation. Proced-
ure success was defined as device success and no major peri-
procedural complications (Emergent CABG, coronary perforation
requiring pericardial drainage, residual dissection impairing vessel
flow—TIMI-flow II or less). Clinical success was defined as proced-
ural success and no in-hospital major adverse cardiac events
(MACE). All deaths were considered cardiac unless an undisputed
non-cardiac cause was identified. Myocardial infarction (MI) and scaf-
fold thrombosis were defined according to the Academic Research
Consortium definition.18 Target-lesion revascularization (TLR) was
defined as clinically driven if at repeat angiography the diameter sten-
osis was.70%, or if a diameter stenosis.50% was present in asso-
ciation with (i) presence of recurrent angina pectoris, related to the
target vessel; (ii) objective signs of ischaemia at rest (ECG changes) or
during exercise test, related to the target vessel; and (iii) abnormal
results of any functional diagnostic test.
Thedevice-orientedendpoint target-lesion failurewasdefinedasthe
composite of cardiac death, target-vessel MI, or ischaemia-driven TLR.
Majoradverse cardiaceventsdefinedasthecompositeofcardiacdeath,
any re-infarction (Q- or non-Q-wave), emergent bypass surgery
(CABG), or clinically driven TLR. Target-vessel failure (TVF) was
defined as cardiac death, target-vessel MI, or clinically driven TVR.
Ethics
This is an observational study, performed according to the privacy
policy of the Erasmus MC and to the Erasmus MC regulations for
the appropriate use of data in patient-oriented research, which are
based on international regulations, including the declaration of
Helsinki. The BVS received the CE mark for clinical use, indicated
for improving coronary lumen diameter in patients with ischaemic
heart disease due to de novo native coronary artery lesions with no
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restriction in terms of clinical presentation. Therefore, the BVS can
be currently used routinely in Europe in different settings comprising
the acute MI without a specific written informed consent in addition
to the standard informed consent to the procedure. Given this back-
ground, a waiver from the hospital Ethical Committee was obtained
for written informed consent, as according to Dutch law written
consent is not required, if patients are not subject to acts other
than as part of their regular treatment.
Study device
The second-generation everolimus-eluting BVS is a balloon expand-
able device consisting of a polymer backbone of poly-L-lactide acid
(PLLA) coated with a thin layer of amorphous matrix of poly-D and
-L-lactide acid (PDLLA) polymer (strut thickness 157 mm). The
PDLLA controls the release of the antiproliferative drug everolimus
(100 mg/cm2), 80% of which is eluted within the first 30 days. Both
PLLA and PDLLA are fully bioresorbable. The polymers aredegraded
via hydrolysis of the ester bonds and the resulting lactate and its oli-
gomers are metabolized by the Krebs cycles. Small particles (,2 mm
in diameter) may be also phagocytized and degraded by macro-
phages.19 According to preclinical studies, the time for complete
bioresorption of the polymer backbone is 2–3 years.20 The BVS
edges contain two platinum markers for accurate visualization
during angiography or other imaging modalities.
Quantitative coronary angiography
analysis
Quantitative coronary angiography (QCA) analyses were performed
using the Coronary Angiography Analysis System (Pie Medical
Imaging, Maastricht, Netherlands).
Analyses were performed at pre-procedure, after thombectomy,
after balloon dilatation, and after the BVS implantation with a meth-
odology already reported.21
In caseof thrombotic total occlusion, pre-procedureQCAanalysis
was performed as proximally as possible from the occlusion (in case
of a side branch distally to the most proximal take off of the side
branch). Intracoronary thrombus was angiographically identified
and scored in five grades as previously described.22 Thrombus
grade was assessed before procedure and after thombectomy.
The QCA measurements included reference vessel diameter
(RVD)—calculated with interpolate method—percentage diameter
stenosis, minimal lumen diameter (MLD), and maximal lumen diam-
eter (Dmax). Acute gain was defined as post-procedural MLD minus
pre-procedural MLD (MLD value equal to zero was applied when
culprit vessel was occluded pre-procedurally). Complications occur-
ring any time during the procedure, such as dissection, spasm, distal
embolization, and no-reflow were reported. As additional informa-
tion, MI SYNTAX I and MI SYNTAX II scores providing long-term
risk stratification for mortality and MACE in patients presenting
with STEMI were assessed.23
Optical coherence tomography image
acquisition and analysis
Optical coherence tomography imaging after the BVS implantation
was encouraged in all patients but was not mandatory, subordinated
to device availability and left at the operator’s discretion.
Therefore, OCT imaging of the culprit lesion after treatment was
performed in a subset of the population. The image acquisition was
performedwithC7XR imaging console and the Dragonfly intravascu-
lar imaging catheter (both St. Jude Medical, St. Paul, MN, USA). Image
acquisition has been previously described.24 Briefly, after positioning
the OCT catheter distally to the most distal scaffold marker, the cath-
eter is pulled back automatically at 20 mm/s with simultaneous con-
trast infusion by a power injector (flush rate 3–4 mL/s). In cases
where the entire scaffold region was not imaged in one pullback, a
second more proximal pullback was performed for complete visual-
ization. Images were stored and analysed offline.
Analysis of the OCT images was performed with theSt Jude/Lightlab
offline analysis software (St. Jude Medical), using previously described
methodology for BVS analysis.17 Analysis was performed in 1-mm lon-
gitudinal intervals within the treated culprit segment, after exclusion of
frames with ,75% lumen contour visibility. Lumen, scaffold, and
incomplete scaffold apposition (ISA) area were calculated in accord-
ance with standard methodology for analysis of bioresorbable scaf-
folds17 (Figure 1A and B), while in sites with overlapping scaffolds,
analysis was performed using previously suggested modifications25
(Figure 1D). Specifically, the lumen contour is traced at the lumen
border and in the abluminal (outer) side of apposed struts, while in
the case of malapposed struts the contour is traced behind the
malapposed struts. In cases where the scaffold struts are completely
covered by tissue or thrombus, the lumen contour is traced above
the prolapsing tissue (Figure 1C). The scaffold area is traced following
interpolation of points located in the mid-point of the abluminal
border of the black core in apposed struts and the mid-point of the
abluminal strut frame border in malapposed or side branch-related
struts, so that the scaffold area is identical to the lumen area in the
absence of ISA and tissue prolapse. Incomplete scaffold apposition
area is traced in the case of malapposed struts as the area delineated
between the lumen and scaffold contours (Figure 1B).
A special consideration should be mentioned concerning BVS ana-
lysis in MI with the presence of increased tissue prolapse and residual
thrombus post-implantation21,26 (Figures 1C and 2). Tissue prolapse
area can be quantified as the difference between the scaffold and
the lumen area. For the calculation of prolapse area, in the case
that one or more scaffold struts are completely covered by thrombus
or tissue, the total black core area of these struts is also measured.
Prolapse area is then calculated as [scaffold area + ISA area2
lumen area2 embedded black core area]. The area of non-attached
intraluminal defects (e.g. thrombus) is also measured. Atherothrom-
botic area is then calculated as the sum of prolapse area and intralum-
inal defect area and normalized as a percent ratio of the scaffold area
(atherothrombotic burden, ATB).21,26 It should be noted that in the
case of bioresorbable scaffolds where measurements of the scaffold
area are performed using the abluminal side of the scaffold struts,
ATB is overestimated compared with metal platform stents where
measurements of the stent area are performed from the adluminal
(inner) side of the struts. Additionally, flow area was assessed as
[scaffold area + ISA area2 atherothrombotic area2 total strut
area] and the minimal flow area was recorded.
A scaffold strut is defined as incompletely apposed when there is
no contact between the abluminal border of the strut and the
vessel wall. This does not include struts located in front of side
branches or their ostium (polygon of confluence region), which are
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defined as side branch-related struts. Intraluminal struts that are part
of adjacent clusters of apposed struts in overlapping scaffolds are also
not considered malapposed.25 For illustrative proposes, OCT
bi-dimensional images are reported by three-dimensional rendering
by dedicated software (Intage Realia, KGT, Kyoto, Japan)17 (Figures 2
and 3).
Statistical analysis
Continuous variables are presented as mean and standard deviation,
and categorical variables are reported as count and percentages. De-
scriptive statistics was provided for all variables. The present study is
intended to be a ‘first experience investigation’ evaluating feasibility
and acute performance of the everolimus-eluting BVS for the treat-
ment of patients presenting with STEMI. A patient population of at
least 30 patients was planned to be included in the present study.
Comparisons among multiple means were performed with analysis
of variance (one-way ANOVA). Score (Wilson) confidence intervals
were reported for measures of success.Type A intraclass correlation
coefficients (ICCs) for absolute agreement were used for assessing
intra- and interobserver agreement, while measurement error and
95% limits of agreement were assessed by Bland–Altman analysis.
The ICCs were computed with a two-way random effects model
(single measures). All statistical tests were performed with SPSS,
version 15.0 for windows (IL, USA).
Results
From 1 November 2012 to 30 April 2013, a total of 267 patients pre-
sented with acute MI. Twenty-one of those patients were treated
percutaneously without any stent implantation (thrombectomy or
balloon dilatation alone). Seventy-four had a culprit lesion located
in a coronary vessel with a vessel diameter out of the range availability
of the BVS (i.e. RVD .4.0 mm). Out of the remaining 172 patients,
125 were meeting the inclusion and none of the exclusion criteria
of the present study (47 patients excluded for age, previous PCI or
CABG, left main disease). Seventy-six of those patients were
treated with metal stents and 49 cases (48 implanted with BVS)
were enrolled in the present study (Figure 4, Table 1). Therefore,
the patients implanted with BVS constitute the ~38% of the patients
eligible for the present investigation.
Figure1 Methodology of optical coherence tomography analysis. (A) Good scaffold apposition and absence of incomplete scaffold apposition or
tissue prolapse, (B) incomplete scaffold apposition, (C) sites with high tissue prolapse and struts completely covered by thrombus, and (D) overlap-
ping scaffolds. Upper panel showsbaseline images, middle panel showsquantitative measurements, and lower panel showsmethodology for analysis.
ISA, incomplete scaffold apposition; ATA, atherothrombotic area.
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Baseline clinical characteristics of the 172 patients (49 patients
included in the intent-to-treat population and 123 patients implanted
with metal stents) with vessels size in the range of the BVS availability
are reported in Table 1. In the intent-to-treat population thirty-eight
patients were male (77.6%), mean age was 58.9+10.5 years. Lesions
were distributed as follows: left anterior descending 21 (42.9%), right
coronary artery 22 (44.9%), and circumflex 6 (12.2%). Baseline clin-
ical data of the enrolled patients were compared with the general
population presenting with acute MI and implanted with a metal
stent in vessels theoretically suitable for BVS implantation. Minimal
differences were observed between the two groups. Namely, age
58.9+10.5 vs. 66.4+ 12.2, P, 0.001 and previous PCI 0% vs.
12.2%, P ¼ 0.007. All the other clinical characteristics of the two
populations did not show any significant difference.
Mean door-to-balloon time was 31.3+19.5 min. All patients were
treated with unfractionated heparin at the dose of 70–100 UI/kg and
dual antiplatelet therapy (aspirin plus, prasugrel in 45 patients or clopi-
dogrel in 4 patients). Manual thrombectomy was performed in 38
patients. In 16 cases, direct stenting was performed; a total of 65 scaf-
folds were implanted (12 patients received overlapping scaffolds—
overlap was systematically intended to be minimal). The scaffolds
lengths used were 12, 18, and 28 mm, with scaffolds diameters 2.5,
3.0, and 3.5 mm. Mean scaffold length per-lesion was 26.40+
13.86 mm, mean scaffold diameter per-lesion was 3.2+34 mm. A
highly supportive wire was used in five cases and radial approach was
performed in 26 patients (53.0%) (Table 2). The procedural success
was 97.9% (48/49 patients); in one patient, the delivery of the BVS
was unsuccessful (due to the remarkable vessel tortuosity was not
Figure 2 Bioresorbable vascular scaffolds implantation in a culprit and a non-culprit lesion in myocardial infarction. (A) Coronary angiography
demonstrating a stenotic lesion in proximal LAD (proximal non-culprit lesion) and a total occlusion of the mid-LAD (culprit lesion). (B) Angiography
following thrombusaspiration. (C)Angiography following implantationof a3.5 × 12 mmbioresorbablevascular scaffolds at theproximalLAD lesion
and a 3.0 × 28 mm bioresorbable vascular scaffolds at the mid-LAD lesion. (D) Optical coherence tomography image from the proximal non-culprit
lesion showing absence of tissue prolapse and thrombus in the 3.5 × 12 mm scaffold. (E and F) Optical coherence tomography images from the
culprit lesion showing complete coverage of the bioresorbable vascular scaffolds by tissue prolapse and presence of small amount of intraluminal
defect. (G) Three-dimensional optical coherence tomography rendering in the proximal non-culprit lesion with complete scaffold visualization in-
dicating the absence of prolapsing material. (H) Conversely, in the three-dimensional rendering of the culprit lesion, the morphology of the bior-
esorbable vascular scaffolds cannot be fully visualized due to high levels of tissue prolapse (*).
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possible to advance the BVS at the site of the lesion) and a metallic DES
was implanted. Clinical success was 97.9% (48/49 patients).
Quantitative coronary angiography
analysis
The QCA is reported only in patients implanted with BVS. In 50.0% of
those patients, pre-procedure TIMI-flow was 0 and the RVD was
2.94+0.77 mm. In the non-totally occluded vessels, the RVD was
2.62+0.63 mm, with an MLD of 0.75+ 0.44 mm and a mean diam-
eter stenosis of 70.8+12.5%. After thrombectomy and balloon dila-
tation, TIMI-flow grade 0 was present in 2.5 and 0.0% of patients,
respectively, and TIMI-flow III in 52.5 and 59.3% of the cases, respect-
ively. After the scaffold implantation, there were no cases of TIMI-
flow 0, and a TIMI-flow III was achieved in 91.7% of patients, the
mean post-procedure in-scaffold % diameter stenosis was 14.7+
8.2%, in-scaffold MLD was 2.44+0.49 mm (Table 3). No angiogra-
phically visible residual thrombus was observed at post-procedure.
Optical coherence tomography findings
Optical coherence tomography analysis was performed in a sub-
group of 31 patients implanted with BVS. Mean lumen area was
8.02+1.92 mm2, minimum lumen area 5.95+1.61 mm2, and
minimum flow area 5.62+1.66 mm2. Incomplete scaffold appos-
ition (ISA) was observed in 20 patients with a mean ISA area of
0.118+0.162 mm2 and a mean percentage of malapposed struts
per patients equal to 2.80+ 3.90%. The mean prolapse area was
0.60+0.26 mm2, and the mean intraluminal defect area was
0.013+ 0.017 mm2. Scaffolds with .5% malapposed struts were 7
(Table 4). The OCT analysis stratified by scaffold size (5 BVS
2.5 mm, 13 BVS 3.0 mm, 24 BVS 3.5 mm) showed different lumen,
scaffold, and flow areas, but similar amounts of incomplete stent ap-
position, plaque prolapse, and intraluminal mass areas (Table 5). In
three cases, the observation of scaffold malapposition by OCT,
guided an additional post-dilatation and in one patient the visualiza-
tion of considerable intraluminal thrombus as assessed by OCT led
to a repeated thrombus aspiration.
Intra-observer variability was excellent. Intraclass correlation
coefficients were 0.999 for lumen area and 0.999 for scaffold area,
and the corresponding measurement errors and limits of agreement
were0.01 mm2 (20.12 to0.15 mm2) for lumenarea and20.01 mm2
(20.20 to0.17 mm2) for scaffold area. Similarly, inter-observer intra-
class correlation coefficients were 0.997 for lumen area and 0.987 for
scaffold area, and the corresponding measurement errors and limits
of agreement were20.01 mm2 (20.30 to 0.28 mm2) for lumen area
and 20.22 mm2 (20.68 to 0.24 mm2) for scaffold area.
Clinical outcomes
At the 30-day follow-up, the rate of the device-oriented endpoint,
target-lesion failure, was 0%. None of the patients experienced
target-vessel re-infarction, emergent bypass surgery, or clinically
driven TLR. No cases of cardiac death or scaffold thrombosis were
reported. The MACE rate was 2.6% as one patient, after discharge
developed a non-Q-wave MI related to a non-target-vessel lesion
and underwent a non-target-vessel revascularization within the
Figure 3 Bioresorbable vascular scaffold implantation in a thrombotic bifurcation lesion treated with provisional approach. (A) Coronary angi-
ography pre-intervention. (B) Angiography following bioresorbable vascular scaffold implantation in the LAD, showing pinching of the ostium of
the diagonal (D). (C) Final angiographic result following side branch dilation with 2.0 × 15 mm balloon. (D–F and J) Optical coherence tomography
cross-sectional images and l-mode after bioresorbable vascular scaffolds implantation showing the compromise of the side branch after implantation
and presenceof thrombusat the side branch ostium. (G– I andK)Optical coherence tomographycross-sectional images and l-mode after side branch
dilation, showing the opening of the carina of the side branch. (L and M) Three-dimensional reconstructions confirm the opening of the side branch
ostium.
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30 days post-procedure. This was the only event reported in the
studied population (Table 6).
Discussion
The everolimus-eluting BVS has been tested so far only in elective
patients with stable, unstable angina, or silent ischaemia;16,17,27– 29
showing promising results up to 4-year follow-up30 for the first-
generation and up to 2 years for the second-generation BVS.12,13,31
The present study represents an early investigation reporting clinical
and angiographic data on the use of the second-generation BVS for
the treatment of patients presenting with STEMI and evaluating
acute results with high-resolution intracoronary imaging (OCT).
A high device, procedural, and clinical success rates wereobserved
with all the scaffolds achieving a residual stenosis ,30% and no
in-hospital MACE. Such data are supportive of feasibility and good
acute performance of the BVS for the treatment of patients with
acute MI.
Angiographic data
The everolimus-eluting BVS was implanted in patients presenting
with ST-segment elevation and a thrombus burden 4 or 5 in 63.0%
of the cases. A theoretical concern related to the implantation of
the BVS in such thrombotic lesions is the fact that scaffold positioning
and placement may need a more aggressive lesion preparation (pre-
dilatation) compared with standard metal devices, due to its slightly
higher profile. We hypothesized that this strategy might be prone
to an increase in distal embolization following balloon inflations,
favouring no-reflow and reducing the rate of final TIMI-flow III.
However, the analysis of the post-procedural angiographies
revealed a TIMI-flow III in 91.7% of the cases; such results are in
line with recently reported large trials evaluating the performance
of metallic stents in patients presenting with acute MI.5,6 Less throm-
bus embolization may result from a different pattern of thrombus dis-
lodgment and compression to the arterial wall after deployment of a
device with a larger strut width (157 mm) compared with currently
available metallic stents. The percentage of vessel wall area
Figure 4 Flow-chart of the study. From 1 November 2012 to 30 April 2013, a total of 267 patients presented with acute myocardial infarction.
Twenty-one of thosepatientswere treated percutaneously but without anystent implantation (thrombectomyorballoondilatation alone). Seventy-
four had a culprit lesion located in a coronary vessel with a vessel diameter out of the range availability of the bioresorbable vascular scaffolds (i.e.
reference vessel diameter .4.0 mm). Out of the remaining 172 patients, 125 were meeting the inclusion and none of the exclusion criteria of the
present study (47 patients excluded for age, previous PCI or CABG, left main disease). Seventy-six of those patients were treated with metal stents
and 49 cases (48 implanted with BVS) were included in the present study.
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covered by the BVS polymer (scaffold/vessel ratio) has been previ-
ously evaluated to be 26%,32 a value considerably higher compared
with what observed for conventional metallic DES (i.e. EES provides
a percentage stent/vessel ratio equal to 12%).32 This characteristic of
the BVS might be associated to an increased capacity of capturing
debris and thrombotic material behind the struts before emboliza-
tion to distal microcirculation. This so-called snow racket concept
(entrapment of thrombotic material between the stent and the
vessel) is currently thebasis for the designof noveldevices andclinical
studies.33
Optical coherence tomography findings
Given its high resolution, OCT allows the assessment of in vivo strut
apposition and presence of thrombus.24,34–36
The present analysis was performed at 1 mm intervals in the OCT
pullback. Although, the possibility for a more strict assessment of
OCTanalysis in thrombotic lesionmay beconsidered,21 thismethod-
ology is the current standard applied in our institution for clinical
studies, and the most commonly used in the literature.
Previous reports defined a stent malapposed if at least 5% of struts
were observed to be malapposed;37,38 in the present investigation,
only seven scaffolds (22.6%) investigated with OCT showed a strut
malapposition of .5%, with an overall mean struts malapposition
equal to 2.8+ 3.90%. A recently reported study using a similar meth-
odology to investigate malapposition after metallic balloon expand-
able stent implantation in STEMI patients showed a total of 37.1%
malapposed stents (stents with .5% malapposition) with a mean
percentage of strut malapposition equal to 5.99+7.28%.38 In add-
ition, the mean ISA area was 0.118+ 0.162 mm2, a value in line
with data reported for metallic stent implantation in patients present-
ing with STEMI.21,38 Similarly, the amount of intraluminal defect after
scaffold implantation was minimal and comparable with what is
observed in metallic stents.21 Notably, these results were consistent
among different scaffold sizes.
Clinical outcomes
In the present series, none of patients treated with BVS experienced a
clinical event related to the treated vessel at the 30-day follow-up.
These observations support the feasibility of BVS implantation in
patients presenting with acute STEMI.
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Table 2 Procedural data intent-to-treat population
Procedural data N 5 49
Medications
Aspirin, n (%) 49 (100)
Prasugrel, n (%) 45 (91.8)
Clopidogrel, n (%) 4 (8.2)
Glycoprotein IIb/IIIa antagonists, n (%) 17 (34.7)
Unfractionated heparin, n (%) 49 (100)
Mean door-to-balloon time (min) 31.3+19.5
Manual thrombectomy, n (%) 38 (77.5)
Direct stenting, n (%) 16 (32.7)
Pre-dilatation, n (%) 33 (67.3)
Mean pre-dilatation balloon diameter
per-lesion (mm)
2.6+0.67
Post-dilatation, n (%) 10 (20.4)
Mean post-dilatation balloon diameter
per-lesion (mm)
3.5+0.47
Overlapping, n (%) 12 (24.5)
Overlap scaffolds diameters 3.5 mm–3.5 mm, n (%) 5 (10.2)
Overlap scaffolds diameters 3.5 mm – 3 mm n (%) 5 (10.2)
Overlap scaffolds diameters 3.5 mm–2.5 mm, n (%) 1 (2.0)
Overlap scaffolds diameters, 3 mm–2.5 mm, n (%) 1 (2.0)
Total number of scaffolds, n. 65
Mean scaffolds per-lesion, n. 1.35+0.60
Mean scaffold length per-lesion (mm) 26.40+13.86
Mean scaffold diameter per-lesion (mm) 3.2+34
Supportive wire, n. (%) 5 (10.2)
Radial approach, n. (%) 26 (53.0)
Data are expressed as mean+ SD or number and proportion, n (%).
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Table1 Baselineclinical characteristics intent-to-treat
population andpatients treatedwithmetallic stent in the
enrolment period
Clinical characteristics BVS
(N 5 49)
Metal stents
(N 5 123)
P-value
Age (year) 58.9+10.5 66.4+12.2 ,0.001
Male, n (%) 38 (77.6) 93 (75.6) 0.845
Hypertension, n (%) 19 (38.8) 53/105 (50.5) 0.225
Hypercholesterolemia, n (%) 11 (22.4) 30/100 (30.0) 0.435
Diabetes, n (%) 4 (8.2) 14/116 (12.1) 0.590
Smoke, n (%) 27 (69.2) 46/116 (39.7) 0.120
Family history of CAD, n (%) 12 (24.5) 31/95 (32.6) 0.343
Peripheral vascular
disease, n (%)
1 (2.0) 8 (6.5) 0.449
Kidney disease, n (%) 1 (2.0) 7 (5.7) 0.442
Prior MI, n (%) 1 (2.0) 14 (11.4) 0.070
Prior PCI, n (%) 0 (0.0) 15 (12.2) 0.007
Prior CABG, n (%) 0 (0.0) 3 (2.4) 0.559
COPD, n (%) 2 (4.1) 5 (4.1) 1.000
Culprit vessel 0.624
LM, n (%) 0 (0) 2 (1.6)
LAD, n (%) 21 (42.9) 52 (42.3)
RCA, n (%) 22 (44.9) 46 (37.4)
LCX, n (%) 6 (12.2) 21 (17.1)
SVG, n (%) 0 (0) 2 (1.6)
Patients with vessels diameters not feasible for BVS implantation (i.e. reference
vessel diameter ≥4.0 mm) were excluded.
Data are expressed as mean+ SD or number and proportion, n (%).
CAD, coronary artery disease; MI, myocardial infarction; PCI, percutaneous
coronary intervention; CABG, coronary artery bypass graft; COPD, chronic
obstructive pulmonary disease; LM, left main; LAD, left anterior descending; RCA,
right coronary artery; LCX, circumflex; SVG, saphenous vein graft.
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Table 3 Angiographic analysis in patients implanted
with bioresorbable vascular scaffolds
Angiographic data N 5 48
Pre-procedure
TIMI-flow, % (n)
0 50.0% (23/46)
1 15.2% (7/46)
2 21.7% (10/46)
3 13.0% (6/46)
Thrombus burden, % (n)
0 0.0% (0/46)
1 6.5% (3/46)
2 17.4% (8/46)
3 13.0% (6/46)
4 13.0% (6/46)
5 50.0% (23/46)
Total occlusion (N ¼ 23)
RVD (mm) 2.94+0.77
Non-total occlusion (N ¼ 23)
RVD (mm) 2.62+0.63
MLD (mm) 0.75+0.44
Diameter stenosis (%) 70.8+12.5
After thrombectomy
TIMI-flow, % (n)
0 2.5% (1/40)
1 7.5% (3/40)
2 37.5% (15/40)
3 52.5% (21/40)
Thrombus burden, % (n)
0 0.0% (0/40)
1 30.0% (12/40)
2 35.0% (14/40)
3 22.5% (9/40)
4 10.0% (4/40)
5 2.5% (1/40)
After pre-dilatation
TIMI-flow, % (n)
0 0.0% (0/27)
1 7.4% (2/27)
2 33.3% (9/27)
3 59.3% (16/27)
Before BVS implantation
RVD (mm) 2.63+0.53
MLD (mm) 1.21+0.46
Diameter stenosis (%) 53.2+16.1
Dmax (mm) 3.01+0.52
Post-procedure
TIMI-flow, % (n)
0 0.0% (0/48)
1 0.0% (0/48)
Continued
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Table 3 Continued
Angiographic data N 5 48
2 8.3% (4/48)
3 91.7% (44/48)
In-scaffold
RVD (mm) 2.86+0.52
MLD (mm) 2.44+0.49
Diameter stenosis (%) 14.7+8.2
In-segment
RVD (mm) 2.74+0.59
MLD (mm) 2.20+0.53
Diameter stenosis (%) 21.8+12.0
MI syntax score Ia 10.0 (7.0–15.0)
MI syntax score IIa 7.0 (4.25–10.0)
Dominant right coronary artery, % (n) 93.8% (45/48)
Scaffold-to-artery ratio 1.19+0.24
Complications occurring any time during the procedure, % (n)
Dissection 6.3% (3/48)
Spasm 4.2% (2/48)
Distal embolism 14.6% (7/48)
No-reflow 2.1% (1/48)
Data are expressed as mean+ SD or proportion (%).
aMI syntax scores I and II are expressed as median (interquartile range).
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Table 4 Optical coherence tomography findings
post-implantation in patients implanted with
bioresorbable vascular scaffolds
OCT variables N 5 31
Analysed length (mm) 28.16+ 13.29
Analysed struts, n 245+ 135
Minimum lumen area (mm2) 5.95+ 1.61
Mean lumen area (mm2) 8.02+ 1.92
Lumen volume (mm3) 225.78+ 113.63
Minimum scaffold area (mm2) 6.69+ 1.94
Mean scaffold area (mm2) 8.54+ 1.97
Scaffold volume (mm3) 240.07+ 118.48
Minimum flow area (mm2) 5.62+ 1.66
ISA area (mm2) (N ¼ 20) 0.118+ 0.162
Mean prolapse area (mm2) 0.60+ 0.26
Mean intraluminal defect area (mm2) 0.013+ 0.017
Maximum intraluminal defect area (mm2) 0.094+ 0.077
Mean atherothrombotic area (mm2) 0.61+ 0.27
Mean atherothrombotic burden (%) 7.29+ 3.12
Malapposed struts per patient (%) 2.80+ 3.90
Scaffolds with at least 1 malapposed strut, n (%) 20 (64.5)
Scaffolds with .5% malapposed struts, n (%) 7 (22.6)
ISA, incomplete scaffold apposition.
Data are expressed as mean+ SD or number and proportion, n (%).
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Data showed in the present report with optimal acute perform-
ance in terms of final TIMI-flow and scaffold apposition may suggest
that everolimus-eluting BVS could be considered for the treatment
of patients presenting with STEMI, however, due to the limited
number of patients and events, caution should be made in reaching
firm conclusions. Further larger studies are needed to fully evaluate
the performance of the present device in STEMI patients.
Limitations
The present study represents a feasibility study with a limited number
ofpatients.The small sample sizedoesnot allowreaching conclusions
in terms of clinical outcomes. The lack of a head-to-head comparison
with the current standard of care is a major limitation of the present
study. A longer follow-up is needed to fully evaluate the performance
of this novel device in patients presenting with acute MI. During the
enrolment period, the implantation of either metallic stent or BVS
in STEMI patients was left to the operator’s discretion; this method-
ology may be prone to selection bias. Therefore, these data should
not stimulate at the current state of knowledge the use of BVS in
patients presenting with acute MI. Larger randomized studies are
needed to confirm these preliminary observations.
Conclusion
In the present investigation, the implantation of the everolimus-eluting
BVSwasobserved tobe feasible inpatientspresentingwithSTEMIwith
optimal acute performance. These data are preliminary and need
further confirmation in randomized controlled trials to define the
true role of BVS for the treatment of patients presenting with acute
myocardial infarction.
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Table 5 Optical coherence tomography findings post-implantation stratified by scaffold size in patients implanted with
bioresorbable vascular scaffolds
OCT variables
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ISA area (mm2) (N ¼ 25) 0.190+0.318 (N ¼ 3) 0.063+0.072 (N ¼ 10) 0.133+0.177 (N ¼ 12) 0.429
Mean prolapse area (mm2) 0.40+0.19 0.54+0.27 0.62+0.29 0.246
Mean intraluminal defect area (mm2) 0.007+0.008 0.016+0.021 0.012+0.018 0.628
Maximum intraluminal defect area (mm2) 0.072+0.081 0.102+0.086 0.068+0.065 0.096
Mean atherothrombotic area (mm2) 0.40+0.19 0.56+0.27 0.64+0.30 0.237
Mean atherothrombotic burden (%) 6.00+4.66 7.42+3.79 6.20+3.39 0.594
ISA, incomplete scaffold apposition.
Data are expressed as mean+ SD or number and proportion, n (%).
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Table 6 Clinical outcomes at the 30-day follow-up
intent-to-treat population
Clinical events N 5 49 95% CI
Target-lesion failure (0/49) 0% (0–7.41)
TVF (0/49) 0% (0–7.41)
Cardiac death (0/49) 0% (0–7.41)
Target-vessel MI (0/49) 0% (0–7.41)
Q-wave MI (0/49) 0% (0–7.41)
Non Q-wave MI (0/49) 0% (0–7.41)
Clinically driven target-vessel
revascularization
(0/49) 0% (0–7.41)
Any MI (1/49) 2.6% (0–10.69)
Q-wave MI (0/49) 0% (0–7.41)
Non Q-wave MI (1/49) 2.6% (0–10.69)
Major adverse cardiac events (1/49) 2.6% (0–10.69)
Non-target-vessel revascularization (1/49) 2.6% (0–10.69)
Definite or probable scaffold thrombosis (0/49) 0% (0–7.41)
Data are expressed number and proportion, n (%). 95% CI, 95% confidence interval.
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